Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glipizide and Insulin Glargine for Unstable Diabetes
NCT00732524Phase 4Completed
- Sponsor
- Cook County Health
- Start
- Sep 2004
- Primary completion
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Cook County Health. Primary endpoint: Ability to avoid repeat ED visits or hospitalization at 2 months. Started Sep 2004; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00732524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732524.